AstraZeneca Annual Report and Form 20-F Information 2015

Watch this year in review

2015 at a glance

All growth rates at CER.  

Therapy Areas

AstraZeneca is a global, science-led biopharmaceutical business with an on-market portfolio in our chosen therapy areas.

R&D Capabilities

We have distinctive R&D capabilities in small molecules, biologics, immunotherapies, protein engineering and devices.

We also have personalised healthcare and translational science capabilities.

Global presence

We have a strong global commercial presence, with strength in Emerging Markets.


Our talented employees are committed to achieveing our Purpose in a sustainable way.

61,500 employees worldwide

8,900 employees in R&D

12,500 employees in Manufacturing and Supply

All employee numbers are approximate as at 31 December 2015.

Strategic R&D centres

Increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres.

Cambridge, UK

Gaithersburg, Maryland US

Gothenburg, Sweden

Progressive dividend

Our disciplined capital allocation enables commitment to a progressive dividend.

Net cash shareholder distributions increased to $3,443 million

Dividend per Ordinary Share unchanged

Life-cycle of a medicine

As a global science-led biopharmaceutical company, our activities span the entire life-cycle of a medicine from Research and Development to Manufacturing and Supply to the global Sales and Marketing of primary care and speciality care medicines that transform lives.